Anavex Life Sciences Corp (AVXL)

[sokol]

Yes, great post. Anavex actually made a smart decision on Europe for the Parkinson’s trial as I said in a previous post:

The EU is an excellent choice for the Parkinson's trial. Some of the reasons for saying this are:

1. European Parkinson's experts that have been involved with AVXL 2-73 for several years understand the science behind the drug.
2. They have the credentials and credibility -- at least in Europe.
3. European and (perhaps U.S.) trial participants will be easily recruited.
4. Many more favorable venues for conducting these trials are available in Europe. For example, other young biotech companies have chosen places like the Channel Islands (independent protectrstes of Great Britain) for permission to conduct trials). The result is faster approval of the trials.
5. If success of these trials, and especially any European approval of this drug, will influence the FDA.
6. Any approval of AVXL-273 anywhere in the world will incentive every person and family in the world to seek the drug for these dreaded diseases that AVXL 2-73 may benefit because ALL of these CNS diseases are lacking in treatment.
7. Any approval anywhere will result in faster approval elsewhere.

If I were the CEO of Anavex, I would conduct clinical trials anywhere in the world that may bring this drug to market sooner anywhere in this world. I think Anavex is making a smart move here after a lot of effort and an lot of work to seek the best place possible for the Parkinson's trial. I think the Michael J. Fox Foundation concurs.